Valuation: NGL Fine-Chem Limited

Market Cap 16.06B 169M 151M 139M 126M 236M 240M 1.66B 663M 8.4B 633M 619M 26.62B P/E 2025
32.6x
P/E 2026 26.6x
Enterprise Value 16.84B 177M 158M 146M 132M 247M 251M 1.74B 696M 8.81B 664M 650M 27.92B EV / Sales 2025
1.9x
EV / Sales 2026 2.71x
Free-Float
27.51%
Yield 2025
0.16%
Yield 2026 0.08%
1 day-1.01%
1 week-1.02%
Current month-10.62%
1 month-4.79%
3 months-19.13%
6 months+14.94%
Current year+84.49%
1 week 2,467.6
Extreme 2467.6
2,702.95
1 month 2,467.6
Extreme 2467.6
3,251
Current year 1,322
Extreme 1322
3,595
1 year 1,261
Extreme 1261
3,595
3 years 962.7
Extreme 962.7
3,595
5 years 962.7
Extreme 962.7
3,595
10 years 220
Extreme 220
3,789.45
Manager TitleAgeSince
Chief Executive Officer 61 2015-06-29
Director of Finance/CFO 50 2009-08-27
Compliance Officer - 2026-02-02
Director TitleAgeSince
Chairman 61 2011-08-11
Director/Board Member 50 2010-07-20
Director/Board Member - 2015-08-04
Change 5-day change 1-year change 3-year change Capi.($)
-1.01%-1.02%+72.61%+46.88% 170M
+6.63%+5.13%+68.86%+145.20% 1,148B
+1.53%+2.84%+47.48%+89.01% 652B
+1.68%+1.96%+29.16%+109.31% 505B
+0.73%+2.47%+53.85%+68.96% 384B
+3.83%-0.62%+69.01%+42.32% 348B
+2.38%+4.27%+33.81%+57.95% 294B
+2.26%+3.47%+5.21%+28.92% 264B
+1.97%+3.01%+57.91%+76.14% 244B
+4.03%+5.36%+39.76%+116.14% 197B
Average +2.00%+1.25%+47.77%+78.08% 403.73B
Weighted average by Cap. +2.25%+1.50%+50.23%+95.97%

Financials

2025 2026
Net sales 3.68B 38.67M 34.64M 31.96M 28.92M 54.07M 54.95M 381M 152M 1.93B 145M 142M 6.1B 5.01B 52.61M 47.12M 43.47M 39.34M 73.56M 74.75M 519M 207M 2.62B 197M 193M 8.3B
Net income 211M 2.22M 1.99M 1.83M 1.66M 3.1M 3.15M 21.87M 8.72M 111M 8.33M 8.15M 350M 481M 5.05M 4.53M 4.18M 3.78M 7.07M 7.18M 49.82M 19.88M 252M 18.97M 18.56M 798M
Net Debt 116M 1.21M 1.09M 1M 908K 1.7M 1.73M 11.98M 4.78M 60.55M 4.56M 4.46M 192M 783M 8.22M 7.36M 6.79M 6.15M 11.49M 11.68M 81.04M 32.33M 410M 30.85M 30.19M 1.3B
Projected Income Statement - Annual - NGL Fine-Chem Limited
Logo NGL Fine-Chem Limited
NGL Fine-Chem Limited is an India-based company, which is a manufacturer of pharmaceuticals and intermediates for use in veterinary and human health. The Company caters to various global companies to custom manufacture pharmaceuticals. Its products include APIs Animal Health, APIs Human Health, Intermediates and Specialty Chemicals and Finished Dosage Form. The APIs Animal Health products include Homidium Chloride, Nitroxynil, Clorsulon, Parvaquone, Buparvaquone, Isometamidium Chloride Hydrochloride, Toldimfos Sodium, Butaphosphan, Imidocarb Dipropionate, Triclabendazole, Rafoxanide, Diminazene Aceturate, S-Methoprene, Carprofen and others. The APIs Human Health products include Nitazoxanide and Atovaquone. The Intermediates and Specialty Chemicals product includes 1,4,7-Trimethyl-1,4,7-Triazacylononane and N-Ethyl Glucamine. The Finished Dosage Form products include Diminazene Aceturate Granules and Homidium Chloride Tablets. It has manufacturing plants located around Mumbai.
Employees
498
Date Price Change Volume
26-10-29 ₹2,599.50 -1.01% 149
26-10-28 ₹2,625.95 +0.04% 102
26-10-27 ₹2,625.00 +0.21% 17
26-10-26 ₹2,619.45 -0.94% 320
26-10-23 ₹2,644.20 -0.43% 451
  1. Stock Market
  2. Stocks
  3. NGLFINE Stock